biotech primer logo

THE PRIMER

SCIENCE MADE SIMPLE

Stay Updated! Subscribe to The Primer

Home » Drug Development » Targeted Disruption: The Rise of PARP Inhibitors
Drug Development Executive Certification

Targeted Disruption: The Rise of PARP Inhibitors

by | Sep 2, 2024 | Drug Development

The market for PARP inhibitors, a cornerstone in targeted cancer treatment, is projected to more than triple from $3 billion in 2022 to an estimated $10.3 billion by 2031. This remarkable growth at a CAGR of 14.8% signals a significant shift in oncology care and investment opportunities within the sector.

Why It Matters

With global cancer cases expected to soar to 29.5 million by 2040, the demand for innovative and effective cancer treatments has never been more urgent. PARP inhibitors offer a targeted therapeutic option for individuals with specific genetic mutations, marking a pivotal move toward personalized cancer care.

State of Play

The FDA has greenlit four PARP1 inhibitors to date: Lynparza (olaparib), Zejula (niraparib), Talzenna, and Rubraca. These treatments are not just medical breakthroughs but are also major revenue generators.

The Big Picture

The sector is marked with strategic collaborations and acquisitions, demonstrating confidence in the transformative potential of PARP inhibitors for cancer care:

  • Impact Therapeutics has established a global partnership with Eikon Therapeutics to gain exposure to the PARP1 selective inhibitor IMP1734, which has entered Phase I clinical trials.
  • Gilead Sciences, Inc. has acquired XinThera, a San Diego-based biotech, enhancing its oncology pipeline with access to a range of PARP1-targeted inhibitors, aligning with its strategic focus on oncology development.
  • The $8.5 billion global oncology collaboration between Merck and AstraZeneca has yielded a substantial return, with Merck receiving $1.2 billion in annual revenue from the collaboration last year.
  • Merck’s strategic initiatives also include a significant $169 M investment in HRS-1167, a selective PARP1-blocking drug positioned as a competitor to Lynparza and Zejula, entering an already competitive market.

Driving the News

The Bottom Line

As the PARP inhibitor market rapidly expands, it heralds a new era in cancer treatment and provides opportunities for growth and innovation in the sector. Beyond their established role in oncology, PARP inhibitors also show promise for treating other diseases, such as Amyotrophic Lateral Sclerosis (ALS), and hold immense potential for versatility in the field of precision medicine.

Biotech Primer is your go-to source for interactive training across the biotechnology, pharmaceutical, molecular diagnostics, and medical device sectors. Explore a range of in-depth biotech courses designed to deepen your understanding of key principles and applications in the field.

Learn More

Other Articles You May Be Interested In

Powered By MemberPress WooCommerce Plus Integration